We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
Read MoreHide Full Article
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) stock.
As the major players in the hyper-scale shift of injectable drugs that treat obesity, investors may be pondering which pharmaceutical giant is the better investment at the moment.
Zepbound & Wegovy
Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy are both once-weekly injectable medications designed for chronic weight management. Both have added billions of dollars in additional revenue for these pharmaceutical leaders although Zepbound was more recently approved in November of 2023 while Wegovy has been cleared for usage since June of 2021.
That said, Zepbound has shown greater weight loss, helping patients lose an average of 20.2% of their body weight in a Phase IIIb trial which was 47% more effective than Wegovy.
Growth & Outlook Comparison
Based on Zacks estimates, Eli Lilly’s total sales are now expected to expand 33% in fiscal 2024 to $45.44 billion versus $34.12 billion in 2023. Furthermore, FY25 sales are projected to climb another 33% to $60.36 billion.
More intriguing, Eli Lilly’s annual earnings are slated to soar 108% in FY24 to $13.14 per share compared to EPS of $6.32 in 2023. Plus, FY25 EPS is forecasted to climb another 83% to a whopping $24.04.
Image Source: Zacks Investment Research
Pivoting to Novo Nordisk, its top line is projected to expand 18% in FY24 and is forecasted to increase another 23% in FY25 to $49.03 billion. Novo Nordisk is now expected to post 18% EPS growth in FY24 with annual earnings projected to rise another 22% in FY25 to $3.89 per share.
However, it is noteworthy that FY24 and FY25 EPS estimates are noticeably lower for Novo Nordisk over the last 60 days.
Image Source: Zacks Investment Research
Price Performance Comparison
Over the last year, Eli Lilly’s stock is up a very respectable +25% which has roughly matched the S&P 500 while Novo Nordisk shares are down a lackluster -21%. Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for its new weight-loss drug CagriSema along with patent concerns.
That said, over the last three years, Novo Nordisk stock is up more than +60% to impressively top the broader market although this has noticeably trailed Eli Lilly’s gains of +200%.
Image Source: Zacks Investment Research
Takeaway
Eli Lilly does appear to have the advantage as it relates to expansion in the weight loss drug market with its stock landing a Zacks Rank #3 (Hold). Although there could be better buying opportunities ahead based on Eli Lilly’s valuation, the company's robust top and bottom lines are hard to overlook especially for long-term investors.
In contrast, Novo Nordisk shares land a Zacks Rank #4 (Sell) based on a trend of declining earnings estimate revisions which has started to sour the company’s attractive outlook.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) stock.
As the major players in the hyper-scale shift of injectable drugs that treat obesity, investors may be pondering which pharmaceutical giant is the better investment at the moment.
Zepbound & Wegovy
Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy are both once-weekly injectable medications designed for chronic weight management. Both have added billions of dollars in additional revenue for these pharmaceutical leaders although Zepbound was more recently approved in November of 2023 while Wegovy has been cleared for usage since June of 2021.
That said, Zepbound has shown greater weight loss, helping patients lose an average of 20.2% of their body weight in a Phase IIIb trial which was 47% more effective than Wegovy.
Growth & Outlook Comparison
Based on Zacks estimates, Eli Lilly’s total sales are now expected to expand 33% in fiscal 2024 to $45.44 billion versus $34.12 billion in 2023. Furthermore, FY25 sales are projected to climb another 33% to $60.36 billion.
More intriguing, Eli Lilly’s annual earnings are slated to soar 108% in FY24 to $13.14 per share compared to EPS of $6.32 in 2023. Plus, FY25 EPS is forecasted to climb another 83% to a whopping $24.04.
Image Source: Zacks Investment Research
Pivoting to Novo Nordisk, its top line is projected to expand 18% in FY24 and is forecasted to increase another 23% in FY25 to $49.03 billion. Novo Nordisk is now expected to post 18% EPS growth in FY24 with annual earnings projected to rise another 22% in FY25 to $3.89 per share.
However, it is noteworthy that FY24 and FY25 EPS estimates are noticeably lower for Novo Nordisk over the last 60 days.
Image Source: Zacks Investment Research
Price Performance Comparison
Over the last year, Eli Lilly’s stock is up a very respectable +25% which has roughly matched the S&P 500 while Novo Nordisk shares are down a lackluster -21%. Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for its new weight-loss drug CagriSema along with patent concerns.
That said, over the last three years, Novo Nordisk stock is up more than +60% to impressively top the broader market although this has noticeably trailed Eli Lilly’s gains of +200%.
Image Source: Zacks Investment Research
Takeaway
Eli Lilly does appear to have the advantage as it relates to expansion in the weight loss drug market with its stock landing a Zacks Rank #3 (Hold). Although there could be better buying opportunities ahead based on Eli Lilly’s valuation, the company's robust top and bottom lines are hard to overlook especially for long-term investors.
In contrast, Novo Nordisk shares land a Zacks Rank #4 (Sell) based on a trend of declining earnings estimate revisions which has started to sour the company’s attractive outlook.